Manila Times Business
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs”) for an aggregat
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
SBA Announces Agency-Wide Reorganization to Modernize, Drive Operational Efficiency, and Enhance Accountability to Taxpayers
2h ago
SalesCloser Enters Global Hospitality Sector and Announces Engagement with Major North American Hotel
2h ago
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2h ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2h ago